

Gut Microbiota and Host Plasma Metabolites in Association with Blood Pressure in Chinese Adults

Yiqing Wang¹, Huijun Wang, Annie Green Howard, Matthew C.B. Tsilimigras², Christy L. Avery³, Katie A. Meyer, Wei Sha, Shan Sun, Jiguo Zhang, Chang Su, Zhihong Wang, Anthony A. Fodor, Bing Zhang*, Penny Gordon-Larsen¹*

ABSTRACT: Animal studies have revealed gut microbial and metabolic pathways of blood pressure (BP) regulation, yet few epidemiological studies have collected microbiota and metabolomics data in the same individuals. In a population-based, Chinese cohort who did not report antihypertension medication use (30–69 years, 54% women), thus minimizing BP treatment effects, we examined multivariable-adjusted (eg, diet, physical activity, smoking, kidney function), cross-sectional associations between measures of gut microbiota (16S rRNA [ribosomal ribonucleic acid], N=1003), and plasma metabolome (liquid chromatography-mass spectrometry, N=434) with systolic (SBP, mean [SD]=126.0 [17.4] mmHg) and diastolic BP (DBP [80.7 (10.7) mmHg]). We found that the overall microbial community assessed by principal coordinate analysis varied by SBP and DBP (permutational multivariate ANOVA $P<0.05$). To account for strong correlations across metabolites, we first examined metabolite patterns derived from principal component analysis and found that a lipid pattern was positively associated with SBP (linear regression coefficient [95% CI] per 1 SD pattern score: 2.23 [0.72–3.74] mmHg) and DBP (1.72 [0.81–2.63] mmHg). Among 1104 individual metabolites, 34 and 39 metabolites were positively associated with SBP and DBP (false discovery rate-adjusted linear model $P<0.05$), respectively, including linoleate, palmitate, dihomolinolenate, 8 sphingomyelins, 4 acyl-carnitines, and 2 phosphatidylinositols. Subsequent pathway analysis showed that metabolic pathways of long-chain saturated acylcarnitine, phosphatidylinositol, and sphingomyelins were associated with SBP and DBP (false discovery rate-adjusted Fisher exact test $P<0.05$). Our results suggest potential roles of microbiota and metabolites in BP regulation to be followed up in prospective and clinical studies. (**Hypertension. 2021;77:706–717. DOI: 10.1161/HYPERTENSIONAHA.120.16154.**) • **Data Supplement**

Key Words: blood pressure ■ lipids ■ microbiota ■ metabolome ■ sphingomyelins

Hypertension is a leading modifiable risk factor for cardiovascular disease and mortality.¹ Despite numerous clinical and public health efforts to curb the epidemic, the worldwide prevalence of hypertension has continued to increase over the past decade² and the prevalence of controlled hypertension has remained low.³

The blood pressure (BP) regulatory system is multifactorial, involving interactions among host genetics,⁴ sociodemographic factors, and diet.⁵ The gut microbiota and host metabolome, which may reflect these complex

interactions,^{6,7} have been demonstrated to play fundamental roles in BP regulation in animal models^{8–11} and humans.^{12–14} In particular, the metabolome reflects a thorough snapshot of various metabolic processes, allowing the identification of novel biomarkers and pathogenic pathways of elevated BP.¹⁵ For example, the microbiota-mediated serum 4-hydroxyhippurate is positively associated with incident hypertension in blacks.¹⁶ Additionally, reductions in the overall gut microbial diversity and relative abundance of specific microbial groups, including

Correspondence to: Penny Gordon-Larsen, University of North Carolina at Chapel Hill, Carolina Population Center, 123 W Franklin St, Chapel Hill, NC 27516. Email pglarsen@unc.edu

*These authors contributed equally to this work.

The Data Supplement is available with this article at <https://www.ahajournals.org/doi/suppl/10.1161/HYPERTENSIONAHA.120.16154>.

For Sources of Funding and Disclosures, see page 715.

Hypertension is available at www.ahajournals.org/journal/hyp

Novelty and Significance

What Is New?

- Our study fills the gap in population-based studies investigating both gut microbiota and circulating metabolomics in association with blood pressure (BP).
- Our sample is unique in that many participants with hypertension were untreated, allowing us to minimize the medication effects.

What Is Relevant?

- Our findings support a difference in the overall gut microbiota by BP.

Nonstandard Abbreviations and Acronyms

ARIC	Atherosclerosis Risk in Communities
BMI	body mass index
BDL	below detection limit
BP	blood pressure
CARDIA	Coronary Artery Risk Development in Young Adults
CHNS	China Health and Nutrition Survey
DBP	diastolic BP
FDR	false discovery rate
INTERMAP	International Population Study on Macronutrients and Blood Pressure
LDL-C	low-density lipoprotein cholesterol
PCoA	principal coordinate analysis
SBP	systolic BP

Prevotella and *Coprococcus*, are associated with hypertension in animal models^{11,17} and humans,^{13,14,18} albeit with small sample sizes. However, there is a lack of population-based studies that include microbial and metabolomic data along with phenotypic data, which is necessary to infer how microbiota influence host physiology through bioactive metabolites. Moreover, there is a need for studies conducted in populations with large burdens of hypertension but low rates of diagnosis and treatment for hypertension for the assessment of natural history of BP.

To this end, we used a well-characterized adult cohort from the 2015 China Health and Nutrition Survey (CHNS) to conduct 2 primary analyses: the association between (1) gut microbiota and (2) plasma metabolome with BP. We selected the CHNS because China has the greatest absolute burden of hypertension around the world¹⁹ coupled with a high rates of undiagnosed and untreated hypertension,²⁰ making China an ideal context for studying BP while minimizing the medication effects.

- We identified a novel lipid pattern and several lipid metabolites (eg, sphingomyelins, acyl-carnitines) positively associated with BP.

Summary

In a well-characterized Chinese adult cohort, we showed associations between gut microbiota and plasma metabolites with BP, indicating potential roles of microbial and metabolites groups, like lipids, in BP regulation.

METHODS

The data and code that support the findings of this study are available to researchers upon request. All phenotypic data can be accessed at the CHNS website (<https://www.cpc.unc.edu/projects/china>).

Study Sample

We used data from the 2015 CHNS. The CHNS is a prospective, household-based study across 12 provinces and 3 megacities, which vary substantially in geography, customs, economic development, and health indicators.²¹ Informed consent was obtained for all participants. The study met the standards for the ethical treatment of participants and was approved by the Institutional Review Boards of the University of North Carolina at Chapel Hill and the National Institute for Nutrition and Health, Chinese Center for Disease Control and Prevention. Participants of the 2015 survey aged 30 to 69 years from four southern provinces (Henan, Hunan, Guizhou, Guangxi) with BP data and gut microbiome or plasma metabolome data were eligible for analysis (N=1285, Figure S1 in the [Data Supplement](#)). We excluded participants who were pregnant (n=1), self-reported use of antihypertension medication (n=99), or had missing covariates (n=86). For microbiota analysis, we additionally excluded 35 participants who currently used antibiotics, had diarrhea, inflammatory bowel disease, irritable bowel syndrome, or bowel removal. For metabolites analysis, we additionally excluded 16 participants who had detectable levels of four cardiovascular disease drug metabolites in plasma: metoprolol acid metabolite, alpha-hydroxymetoprolol, nifedipine, and valsartan. The total analysis sample had 1082 adults, with 1003 and 434 adults included in the microbiota and metabolomics analysis samples, respectively.

Blood Pressure

Resting BP was measured by experienced physicians, who had completed a 7-day training session and passed a comprehensive reliability test. After a 5-minute seated rest, systolic (SBP) and diastolic BP (DBP) were measured in triplicate (30-second interval between cuff inflation) using a standard mercury sphygmomanometer (measuring range, 0–300 mmHg) on the right arm (heart level in sitting position) rested on table with

palm face up. The cuff size was selected according to standardized protocol.²² We used the average of the 3 readings as our measure of SBP and DBP. Hypertension was defined as SBP ≥ 140 mmHg, DBP ≥ 90 mmHg, or self-reported diagnosis.²³

Gut Microbiota

Participants collected stool samples at home using the QIAGEN collection kit (QIAGEN, Hilden, Germany) following standardized protocol. Samples were temporarily stored at foam boxes with frozen cold packs and brought to local community or village clinics immediately, where the samples were stored at -20°C . Then, samples were transported in cold-chain to laboratory and frozen at -80°C until processing. Samples were randomized for sequencing at Novogene Bioinformatics Technology, Co, Ltd, Tianjin, China, so that batches were not related to specific collection centers. Bacterial DNA was extracted using TIANGEN DNA extraction kits (TIANGEN Biotech, Beijing, China). Sequencing for 16S rRNA (ribosomal ribonucleic acid) targeting the V4 hypervariable region was performed using primers 515F/806R on the Illumina MiSeq PE250 platform. The raw sequencing reads were processed using the QIIME pipeline,²⁴ with forward and reverse reads merged with fastq-join and filtered using a minimum quality score of 20. No sample was filtered out due to low quality. Operational Taxonomic Units were identified using open-reference method based on a threshold of 0.97, with chimeric Operational Taxonomic Units detected by ChimeraSlayer being removed.²⁵ Taxonomy was assigned based on the SILVA databases (Release 128). We rarefied the resulting taxonomic abundances of 1008 genera to 21 600 sequences/sample to correct for different sequencing depth (21 648–89 427 sequences/sample) before \log_{10} transformation.

Plasma Metabolomics

Fasting blood samples were collected within 3-days of fecal sample collection by clinicians following the same protocol for the collection, processing, and storage. Ethylenediamine tetraacetic acid was used as an anticoagulant and plasma was immediately separated through centrifugation and stored at -80°C . Detection and quantification of metabolites was performed by the partner campus of Metabolon Inc. in China using a nontargeted platform consisting of a Waters ACQUITY ultrahigh performance liquid chromatographer (Milford, MA) and a Thermo Scientific Q-Exactive high-resolution mass spectrometer (Waltham, MA).⁷ Methanol solvent was used to extract plasma samples, which were analyzed with several types of controls, including pooled experiment samples as technical replicate and extracted water samples as process blanks. Signals were extracted, peak identified, and processed using Metabolon's software and hardware. Metabolites were identified by comparing to the mass-to-charge ratio, retention time/index, and chromatographic data in the Metabolon reference library of purified standards and labeled according to Metabolomics Standards Initiative defined identification levels.²⁶ Of the 1104 detected and quantified metabolites, we categorized 131 metabolites that were below detection limits (BDL) in 25% to 50% samples to 3 groups (BDL, $<$ median, \geq median) and 99 metabolites with $>50\%$ of BDL to binary variables (BDL, \geq detection limit). For 874 metabolites with $\leq 25\%$

of BDL, we rescaled the raw area count of each metabolite to a median of one and imputed values BDL by the minimum value before \log_2 transformation.

Covariates

Sociodemographic and behavioral information were collected using standard questionnaires administered by interviewers, including age, sex, education (yes/no completed high school), per-capita household income (household income/number of household member), ever smoking (yes/no), alcohol intake in the past year (yes/no), and total physical activity (metabolic equivalents/wk). We assessed community-level urbanization using a validated urbanization index that encompasses 12 dimensions of urbanization,²⁷ including population density, health infrastructure, sanitation, and transportation. We included 2 validated measures of diet, total energy intake (kcal/day),²⁸ and sodium intake (mg/day),²⁹ collected using 3-consecutive 24-hour diet recalls and household food inventories. We also included 3 clinically measured health markers: (1) for kidney function, we used fasting serum creatinine concentration measured by picric acid method on Hitachi 7600 (Tokyo, Japan) to calculate estimated glomerular filtration rate (mL/min per 1.73m^2) based on the Chronic Kidney Disease Epidemiology Collaboration equation³⁰; (2) LDL-C (low-density lipoprotein cholesterol, mg/dL) was measured by the polyethylene glycol-modified enzyme method on Hitachi 7600; (3) we calculated body mass index (BMI) from weight over squared height (kg/m^2) measured using calibrated beam scales and portable stadiometers, respectively.

Statistical Analysis

Primary outcomes were SBP and DBP. In the microbiota analysis sample, we first analyzed the overall gut microbiota by examining the associations of genus-level within-person microbial diversity (α -diversity), measured by Shannon index and richness,^{31,32} and between-person diversity (β -diversity), assessed by principal coordinate analysis (PCoA) based on Bray-Curtis dissimilarity matrix,³³ with SBP and DBP using linear regression and permutational multivariate ANOVA with 999 permutations,³⁴ respectively. PCoA axis score is a weighted sum of genera scores (Table S1). Then, we quantified the association between each of the first four PCoA axes, explaining 8.61%, 5.58%, 3.54%, and 3.16% of microbial variability, respectively, as well as 1008 specific genera with SBP and DBP using linear regression. We treated 110 genera detected in $\geq 25\%$ of the sample as continuous variables and dichotomized the rest 898 rare genera to presence/absence. We adjusted all analyses for the following potential confounders in Model 1 based on a priori knowledge: age, sex, provinces, urbanization index (tertiles),³⁵ education, per-capita household income (tertiles), total energy intake, animal-source food consumption,³⁶ sodium consumption,³⁷ total physical activity (tertiles), tobacco use, alcohol consumption, and estimated glomerular filtration rate.³⁸ As BMI is a potential mediator for microbiota-BP relationship, we additionally adjusted for BMI in Model 2 as a sensitivity analysis to test whether the association was independent of BMI. Additionally, as lipid profile is correlated with BP and microbiota, we conducted a post hoc analysis that additionally adjusted for the atherogenic LDL-C.

In the metabolomics analysis sample, we first analyzed the overall metabolome by separately grouping 874 metabolites (continuous variables, $\leq 25\%$ BDL) into uncorrelated patterns to account for complex correlations across metabolites, using principal component analysis followed by a varimax rotation to improve interpretation.³⁹ Based on 3 criteria: eigenvalues >1 , the point of inflection in scree plot, and interpretability,⁴⁰ we selected 3 metabolite patterns (Table S2). Pattern score is a weighted sum of rotated and inverse factor loadings. Then, we assessed the association between each metabolite pattern, as well as 1104 individual metabolites with SBP and DBP, using the above-mentioned multivariable-adjusted linear models adjusting for batch. We used a Wald test to assess the statistical significance of 131 metabolites with 3 categories (BDL, $<$ median, \geq median). Based on model 1 results for individual metabolites, we calculated pathway enrichment score $[\frac{k}{m} / (\frac{n-k}{N-m})]$ reflecting the degree to which a given pathway was associated with SBP or DBP, where k and n are numbers of BP-associated metabolites in the given pathway and all pathways, respectively, and m and N are numbers of tested metabolites in the given pathway and all pathways, respectively. We performed a Fisher exact test⁴¹ to evaluate whether the presence of BP-associated metabolites among identified compounds from a particular metabolic pathway was greater than expected by chance.

In a subsample of participants with microbiota and metabolite data ($n=355$), we examined the association between BP-associated microbiota features and BP-associated metabolites using linear models to understand the intercorrelation between microbiota and metabolites. Next, we conducted random forest regression (100 trees) which allows interaction across microbiota and metabolites,⁴² followed by 5 iterations of 2-fold cross-validation modified paired t test of root mean squared errors, a powerful test to compare the performance of learning algorithms with acceptable type I error,⁴³ to provide insight into which of the following data as a whole had the strongest association with BP: host factors (14 model 1 covariates), microbiota (1008 genera), metabolites (1104 metabolites), microbiota+host factors, metabolites+host factors, microbiota+metabolites, and microbiota+metabolites+host factors.

We adjusted P values for multiple comparisons using Benjamini-Hochberg method (false discovery rate, FDR)⁴⁴ in comparisons across taxa, metabolites, and metabolic pathways for SBP and DBP separately. All statistical tests were 2-sided with a significance level of 0.05. We used R 3.6.0 (<http://www.r-project.org>) and Python 3.5.1 (<https://www.python.org>) for data analysis.

RESULTS

Our sample had large variation in SBP (mean [SD]: 126.0 [17.4] mmHg) and DBP (80.7 [10.7] mmHg), with 27.6% prevalence of hypertension (Table S3).

We first assessed the overall gut microbial measures. Within-person microbial diversity (Shannon index and richness) was not associated with SBP or DBP (Table S4, $P=0.45-0.97$). Between-person microbial diversity assessed by PCoA varied by SBP (Figure; permutational

multivariate ANOVA $R^2=0.20\%$, $P=0.002$) and DBP (Figure S2; permutational multivariate ANOVA $R^2=0.14\%$, $P<0.05$). Only the fourth PCoA axis showed a clear separation of SBP (Figure), with higher axis




Figure. Microbial between-person diversity (β -diversity) assessed using principal coordinate analysis by systolic blood pressure (SBP).

Centroids illustrate the 95% CI for the mean location of each SBP (mmHg) quartile. Vectors for 10 taxa with the greatest contributions to MDS (multidimensional scaling) 4 indicate the directions and strengths of their correlations with MDS4 (Table S1). In permutational multivariate ANOVA ($N=1003$), SBP had R^2 of 0.20% and P value of 0.002, after adjusting for age, sex, provinces, urbanization index, per-capita household income, education, total energy intake, animal-source food, sodium, physical activity, smoking, alcohol, and estimated glomerular filtration rate. Results remained the same after additional adjustment of body mass index.

score associated with higher SBP (Table S5). This axis was positively correlated with *Rothia*, *Serratia*, *Enterobacteriaceae*, *Leuconostocaceae*, and *Fusobacterium* and negatively correlated with *Coprococcus*, *Adlercreutzia*, *Eggerthella*, and *Raistonia*. However, after correction for multiple hypothesis testing, none of the 1008 specific genera were associated with SBP or DBP at FDR-adjusted $P < 0.05$ (Table S6). We observed similar results after additionally adjusted for LDL-C (Table S7 through S9).

In plasma metabolite analysis, we identified 3 biologically possible patterns using principal component analysis that each explained 9.63%, 4.79%, and 4.69% of variance (Table 1). The second pattern characterized by lipids, like linoleate, palmitate, and oleate/vaccinate was positively associated with SBP (linear model coefficient [95% CI] per 1 SD pattern score: 2.23 [0.72–3.74] mm Hg) and DBP (1.72 [0.81–2.63] mm Hg). The results were slightly attenuated by adjustment of BMI (SBP: 1.88 [0.38–3.38] mm Hg; DBP: 1.45 [0.55–2.35] mm Hg).

To identify whether specific metabolites contributing to this lipid pattern drove the associations with SBP and DBP, we examined 1104 metabolites (Table S10 through S12) and found that 34 and 39 metabolites were associated with SBP (Table 2) and DBP (Table 3) at Model 1 FDR-adjusted $P < 0.05$, respectively, including 8 sphingomyelins, 4 acyl-carnitines, and cholesterol. Among these SBP- and DBP-associated metabolites, 8 (23.5%) and 19 (48.7%) metabolites, respectively,

had high loadings (>0.4) for the lipid pattern, including acyl-carnitines (C16, C26, C14, and C12), 1-palmitoleoylglycerol (16:1), and dihomolinolenate (20:3n3 or 3n6), which were positively associated with both BP measures. In contrast, we saw noticeably fewer SBP- and DBP-associated metabolites with high loadings for the other two metabolite patterns (0%–11.8%). After adjusting for BMI, only 9 and 17 metabolites remained statistically significantly associated with SBP and DBP (model 2 FDR-adjusted $P < 0.05$), respectively, including sphingomyelins (d18:1/23:0, d18:1/24:0, and d18:2/24:2) and acyl-carnitines (C16 and C14). After adjusting for LDL-C, results for metabolite patterns were similar to main model results (Table S13) and only 19 metabolites remained statistically significantly associated with DBP (Table S14).

In pathway analysis that tested whether the number of positive or negative associations between BP and metabolites from a particular metabolic pathway was more than expected by chance (Table 4, Table S15), we found that diacylglycerol, acylcarnitine (long-chain saturated), phosphatidylcholine, phosphatidylinositol, sphingomyelins metabolic pathways were associated with SBP (FDR-adjusted $P < 0.05$); and corticosteroids, acylcarnitine (long-chain saturated and median chain), monoacylglycerol, phosphatidylinositol, and sphingomyelins metabolic pathways were associated with DBP.

In a subsample of 355 participants with similar distributions of SBP (123.5 [16.7] mmHg) and DBP (79.8 [9.9]) to the full sample (Table S16), we conducted

Table 1. Association Between Metabolite Patterns With SBP and DBP (mm Hg), Coefficient (95% CI)

Metabolite pattern	Metabolites contributing to each pattern	Eigenvalue	Variance explained	SBP		DBP	
				Model 1	Model 2	Model 1	Model 2
Pattern 1 (nucleotide, amino acid, and peptide)	Pseudouridine; 2,3-dihydroxy-5-methylthio-4-pentenoate; N-acetylthreonine; N,N-dimethyl-pro-pro; C-glycosyl-tryptophan;	84.19	9.63%	1.81 (–0.24 to 3.86)	1.58 (–0.44 to 3.60)	0.24 (–1.01 to 1.49)	0.06 (–1.16 to 1.28)
Pattern 2 (lipids, especially long-chain fatty acids)	Linoleate (18:2n6); palmitate (16:0); oleate/vaccinate (18:1); 10-heptadecenoate (17:1n7); docosapentaenoate (22:5n3); hexadecadienoate (16:2n6);	41.83	4.79%	2.23 (0.72 to 3.74)†	1.88 (0.38 to 3.38)*	1.72 (0.81 to 2.63)†	1.45 (0.55 to 2.35)†
Pattern 3 (sphingomyelins, eicosanoid, short-chain fatty acids, and branched-chain amino acids)	Sphingomyelin (d18:2/23:0, d18:1/23:1, d17:1/24:1); 3-methyl-2-oxobutyrate; leukotriene B4; 5-hydroxyeicosatetraenoic acid; methionine sulfoxide; butyrate/isobutyrate (4:0);	40.99	4.69%	0.24 (–1.57 to 2.05)	–0.02 (–1.80 to 1.77)	0.14 (–0.96 to 1.24)	–0.05 (–1.13 to 1.02)

Patterns were derived from principal component analysis followed by a varimax rotation of 874 metabolites (N=434). Coefficient indicates SBP or DBP associated with each 1 SD of metabolites pattern score in linear regression. Contributing metabolites are metabolites with the highest absolute loadings for the respective pattern (Table S2). Model 1 was adjusted for age, sex, provinces, batch, urbanization index, per-capita household income, education, total energy intake, animal-source food, sodium, physical activity, smoking, alcohol, and estimated glomerular filtration rate. Model 2 was additionally adjusted for body mass index. DBP indicates diastolic BP; GPE, glycerophosphoethanolamine; and SBP, systolic BP.

* $P < 0.05$.

† $P < 0.01$.

Table 2. Association Between Individual Metabolites and SBP (mm Hg)

Metabolites	Pathway	Loading in lipid pattern*	Model 1		Model 2		
			Coefficient (95% CI)	Q value	Coefficient (95% CI)	Q value	
Tricosanoyl sphingomyelin (d18:1/23:0)†	Sphingomyelins	...	7.56 (4.52 to 10.61)	0.002	6.53 (3.43 to 9.62)	0.015	
Lignoceroyl sphingomyelin (d18:1/24:0)†	Sphingomyelins	...	6.37 (3.59 to 9.14)	0.005	5.61 (2.83 to 8.39)	0.024	
Palmitoylcarnitine (C16)†	Fatty acid metabolism (acyl carnitine, long-chain saturated)	0.50	7.26 (3.97 to 10.56)	0.007	6.95 (3.71 to 10.2)	0.015	
1-myristoyl-2-arachidonoyl-GPC (14:0/20:4)†	PC	...	4.34 (2.32 to 6.37)	0.007	3.53 (1.45 to 5.61)	0.059	
Sphingomyelin (d18:2/24:2)†	Sphingomyelins	...	4.53 (2.41 to 6.64)	0.007	4.46 (2.38 to 6.54)	0.015	
1-palmitoyl-2-linoleoyl-GPI (16:0/18:2)†	PI	...	5.83 (3.02 to 8.64)	0.010	5.38 (2.59 to 8.16)	0.037	
1-palmitoyl-2-arachidonoyl-GPC (16:0/20:4n6)†	PC	...	7.91 (4.01 to 11.82)	0.010	6.7 (2.77 to 10.63)	0.059	
1-palmitoyl-2-arachidonoyl-GPI (16:0/20:4)†	PI	...	4.96 (2.51 to 7.41)	0.010	4.44 (2.01 to 6.87)	0.046	
Sphingomyelin (d18:1/21:0, d17:1/22:0, d16:1/23:0)†	Sphingomyelins	...	6.38 (3.28 to 9.49)	0.010	5.03 (1.82 to 8.25)	0.088	
Behenoyl sphingomyelin (d18:1/22:0)†	Sphingomyelins	...	7.35 (3.57 to 11.14)	0.014	5.91 (2.05 to 9.77)	0.092	
Sphingomyelin (d18:1/14:0, d16:1/16:0)†	Sphingomyelins	...	7.21 (3.4 to 11.01)	0.019	5.65 (1.75 to 9.55)	0.118	
Cerotoylcarnitine (C26)†	Fatty acid metabolism (acyl carnitine, long-chain saturated)	0.42	4.29 (2.02 to 6.56)	0.019	3.91 (1.66 to 6.16)	0.059	
Pantothenate (vitamin B5)	Pantothenate and coenzyme A metabolism	...	7.77 (3.63 to 11.91)	0.019	6.86 (2.74 to 10.97)	0.064	
N2,N2-dimethylguanosine	Purine metabolism, guanine containing	...	8.74 (3.99 to 13.49)	0.020	8.09 (3.4 to 12.78)	0.059	
Cholesterol†	Sterol	...	8.48 (3.89 to 13.07)	0.020	7.67 (3.12 to 12.22)	0.062	
Sphingomyelin (d18:2/14:0, d18:1/14:1)†	Sphingomyelins	...	5.75 (2.58 to 8.91)	0.022	4.57 (1.36 to 7.79)	0.121	
Adrenate (22:4n6)	Long-chain polyunsaturated fatty acid (n3 and n6)	0.71	3.15 (1.36 to 4.93)	0.028	2.9 (1.14 to 4.67)	0.066	
1-palmitoleoylglycerol (16:1)†	Monoacylglycerol	0.57	2.26 (0.98 to 3.53)	0.028	1.75 (0.45 to 3.05)	0.143	
1-palmitoyl-2-palmitoleoyl-GPC (16:0/16:1)	PC	...	3.57 (1.54 to 5.59)	0.028	3.01 (0.98 to 5.04)	0.107	
Myristoylcarnitine (C14)†	Fatty acid metabolism (acyl carnitine, long-chain saturated)	0.53	2.96 (1.27 to 4.64)	0.029	3.01 (1.35 to 4.66)	0.046	
Branched-chain, straight-chain, or cyclopropyl 10:1 fatty acid (1)	Partially characterized molecules	...	2.66 (1.13 to 4.19)	0.030	2.58 (1.07 to 4.08)	0.059	
Sphingomyelin (d18:2/16:0, d18:1/16:1)†	Sphingomyelins	...	8.35 (3.52 to 13.17)	0.031	6.84 (1.99 to 11.69)	0.122	
Picolinoylglycine	Fatty acid metabolism (acyl glycine)	...	3.34 (1.41 to 5.28)	0.031	2.75 (0.81 to 4.69)	0.122	
N6-carbamoylthreonyladenosine	Purine metabolism, adenine containing	...	6.16 (2.54 to 9.78)	0.032	5.57 (1.99 to 9.16)	0.088	
Dihomolinolenate (20:3n3 or 3n6)†	Long-chain polyunsaturated fatty acid (n3 and n6)	0.73	4.25 (1.75 to 6.74)	0.032	3.65 (1.16 to 6.14)	0.113	
1-stearoyl-2-arachidonoyl-GPC (18:0/20:4)	PC	...	6.08 (2.52 to 9.64)	0.032	5.01 (1.44 to 8.58)	0.122	
Acetylcarnitine (C2)	Fatty acid metabolism (acyl carnitine, short chain)	0.50	6.57 (2.63 to 10.5)	0.038	7 (3.13 to 10.86)	0.046	
Retinol (vitamin A)	Vitamin A metabolism	...	5.16 (2.04 to 8.28)	0.040	4.48 (1.39 to 7.58)	0.118	
Argininate	Urea cycle; arginine and proline metabolism	...	3.93 (1.56 to 6.3)	0.040	3.19 (0.81 to 5.57)	0.148	
2,3-dihydroxy-5-methylthio-4-pentenoate	Methionine, cysteine, SAM, and taurine metabolism	...	7.88 (3.11 to 12.66)	0.040	6.51 (1.73 to 11.29)	0.135	
Laurylcarnitine (C12)†	Fatty acid metabolism (acyl carnitine, medium chain)	0.49	2.25 (0.88 to 3.62)	0.042	2.36 (1.02 to 3.71)	0.059	
Metabolites with 25%–50% BDL: reference=BDL							
Linoleoyl-linoleoyl-glycerol (18:2/18:2) [1]	Diacylglycerol	Below median	...	2.29 (–1.6 to 6.17)	0.022	3.5 (–0.37 to 7.37)	0.046
		Above median		–4.56 (–8.39 to –0.73)		–3.45 (–7.26 to 0.36)	

(Continued)

Table 2. Continued

Metabolites	Pathway		Loading in lipid pattern*	Model 1		Model 2	
				Coefficient (95% CI)	Q value	Coefficient (95% CI)	Q value
Oleoyl-linoleoyl-glycerol (18:1/18:2) [2]	Diacylglycerol	Below median	...	-3.07 (-6.99 to 0.85)	0.042	-2.49 (-6.36 to 1.38)	0.088
		Above median		-7.31 (-11.39 to -3.24)		-6.8 (-10.82 to -2.78)	
Metabolites with >50% BDL: reference=BDL							
Phenylalanylalanine	Dipeptide	Above limit of detection	...	-4.86 (-7.86 to -1.85)	0.047	-4.94 (-7.89 to -1.98)	0.064

Coefficient indicates SBP associated with a fold increase of the abundance or per category change of a metabolite in linear regression (N=434). The statistical significance of metabolites with 25-50% BDL was assessed using a Wald test. Model 1 was adjusted for age, sex, provinces, batch, urbanization index, per-capita household income, education, total energy intake, animal-source food, sodium, physical activity, smoking, alcohol, and estimated glomerular filtration rate. Model 2 was additionally adjusted for body mass index. BDL indicates below detection limit; GPC, glycerophosphocholine; GPI, glycerophosphoinositol; PC, phosphatidylcholine; PI, phosphatidylinositol; and SBP, systolic blood pressure.

*Pattern was derived from principal component analysis followed by a varimax rotation. Loadings>0.4 are listed.

†Metabolites also associated with diastolic blood pressure.

integrated microbiota and metabolite analysis to examine the intercorrelation between microbiota and metabolites and whether the microbiota and metabolite data had better BP predictive performance than host sociodemographic and behavioral risk factors. We observed no correlation between the BP-associated, fourth gut microbiota PCoA axis with any of the 54 BP-associated metabolites (Table S17, FDR-adjusted $P \geq 0.27$). Using random forest regression, we found comparable accuracies across host factors, microbiota, and metabolite data in predicting SBP and DBP (Figure S3, $P > 0.05$).

DISCUSSION

In a population-based cohort of middle-aged Chinese adults, we found an association between the overall gut microbiota (between-person diversity) with SBP and DBP, after accounting for a wide range of sociodemographic factors, health behaviors, and kidney function. Using plasma metabolome data, we found that a lipid pattern and several individual metabolites like sphingomyelins, acyl-carnitines, and cholesterol were positively associated with SBP and DBP. Our results suggest that in this population with high prevalence of untreated hypertension (27.6%), gut microbiota, and plasma metabolites may play important roles in hypertension.

Several studies have shown an association between the gut microbiota and BP.^{13,14,18} For example, a recent case-control study of 80 Brazilian adults¹⁴ showed lower microbial biodiversity along with lower proportions of butyrate-producing taxa like *Roseburia*, *Coprococcus*, and *Lachnospiraceae* but higher proportions of *Enterobacteriaceae* and *Lactobacillus* in individuals with high versus normal BP. The Sun et al's¹⁸ article of 529 middle-aged US adults from CARDIA study (Coronary Artery Risk Development in Young Adults) found an inverse cross-sectional association between within-person microbial diversity with SBP and differences in the overall microbial community by SBP. Similarly, we observed differences in the overall gut microbial community by SBP and

DBP in the current CHNS study. The US CARDIA cohort is quite different from the China population-based cohort (eg, higher hypertension medication use, different diet and lifestyle in the US cohort). Furthermore, we excluded participants who used antihypertension medication from the current analysis, whereas 29.2% of participants took antihypertension medications in the CARDIA analysis sample.¹⁸ Future prospective studies are needed to confirm the results of our study and previous research.

Metabolomics studies showing associations between microbial metabolites and BP further support the role of gut microbiota in BP regulation.^{16,45} The INTERMAP study (International Population Study on Macronutrients and Blood Pressure) of 4630 middle-aged adults from United States, United Kingdom, Japan, and China showed that urinary alanine and hippurate were positively and negatively associated with BP, respectively.⁴⁵ The ARIC study (Atherosclerosis Risk in Communities) of 896 Blacks revealed that each one SD increase in baseline serum 4-hydroxyhippurate was associated with 17% higher risk of incident hypertension.¹⁶ In our sample, we found that p-cresol sulfate from benzoate metabolism, a product of tyrosine and phenylalanine metabolism by anaerobic bacteria,⁴⁶ was inversely associated with DBP. Additionally, we found comparable predictive accuracies between gut microbiota and plasma metabolome for BP, indicating that microbiota may play a role in metabolites-BP associations, as it has been shown that gut microbiota is involved in host lipid metabolism and modulates plasma metabolome in response to angiotensin II.^{47,48} Given that many microbiota-mediated metabolites were strongly associated with diet, for example, hippurate derived from dietary polyphenols,⁴⁹ different dietary patterns across populations may relate to these different results across studies.

Host-derived metabolites like the ketone body β -hydroxybutyrate, acyl-carnitines, and long-chain fatty acids have also been suggested in mechanisms of BP regulation.^{15,16,50} For example, nutritional supplementation of a precursor of β -hydroxybutyrate attenuated

Table 3. Association Between Individual Metabolites and DBP (mm Hg)

Metabolites	Pathway	Loading in lipid pattern*	Model 1		Model 2	
			Coefficient (95% CI)	Q value	Coefficient (95% CI)	Q value
Lignoceroyl sphingomyelin (d18:1/24:0)†	Sphingomyelins	...	4.85 (3.19 to 6.52)	2×10 ⁻⁰⁵	4.28 (2.62 to 5.93)	0.001
Behenoyl sphingomyelin (d18:1/22:0)†	Sphingomyelins	...	6.16 (3.9 to 8.43)	1×10 ⁻⁰⁴	5.09 (2.8 to 7.39)	0.004
Tricosanoyl sphingomyelin (d18:1/23:0)†	Sphingomyelins	...	4.95 (3.11 to 6.8)	1×10 ⁻⁰⁴	4.12 (2.26 to 5.98)	0.004
Cerotoylcarnitine (C26) †	Fatty acid metabolism (acyl carnitine, long-chain saturated)	0.42	3.09 (1.71 to 4.46)	0.003	2.79 (1.45 to 4.14)	0.008
Corticosterone	Corticosteroids	...	-1.39 (-2.02 to -0.77)	0.003	-1.11 (-1.74 to -0.49)	0.033
Dihomolinolenate (20:3n3 or 3n6)†	Long-chain polyunsaturated fatty acid (n3 and n6)	0.73	3.28 (1.77 to 4.79)	0.004	2.83 (1.34 to 4.31)	0.020
Sphingomyelin (d18:2/24:2)†	Sphingomyelins	...	2.8 (1.51 to 4.09)	0.004	2.75 (1.5 to 4)	0.004
Myristoylcarnitine (C14)†	Fatty acid metabolism (acyl carnitine, long-chain saturated)	0.53	2.15 (1.13 to 3.17)	0.005	2.19 (1.2 to 3.18)	0.004
Cortolone glucuronide (1)	Corticosteroids	...	2.34 (1.22 to 3.45)	0.005	1.7 (0.56 to 2.83)	0.112
Behenoyl dihydro sphingomyelin (d18:0/22:0)	Dihydro sphingomyelins	...	1.84 (0.95 to 2.72)	0.006	1.2 (0.27 to 2.14)	0.182
Sphingomyelin (d18:1/21:0, d17:1/22:0, d16:1/23:0)†	Sphingomyelins	...	3.85 (1.96 to 5.74)	0.007	2.73 (0.79 to 4.67)	0.133
1-palmitoyl-2-linoleoyl-GPI (16:0/18:2)†	PI	...	3.46 (1.75 to 5.18)	0.007	3.11 (1.43 to 4.79)	0.024
Cis-4-decenoylcarnitine (C10:1)	Fatty acid metabolism (acyl carnitine, monounsaturated)	0.44	1.47 (0.73 to 2.21)	0.008	1.52 (0.81 to 2.24)	0.006
Laurylcarnitine (C12)†	Fatty acid metabolism (acyl carnitine, medium chain)	0.49	1.63 (0.8 to 2.46)	0.009	1.72 (0.91 to 2.52)	0.006
Linoleate (18:2n6)	Long-chain polyunsaturated fatty acid (n3 and n6)	0.80	2.65 (1.26 to 4.04)	0.013	2.44 (1.08 to 3.81)	0.030
Decanoylcarnitine (C10)	Fatty acid metabolism (acyl carnitine, medium chain)	0.48	1.43 (0.67 to 2.19)	0.014	1.46 (0.72 to 2.2)	0.013
1-palmitoleoylglycerol (16:1)†	Monoacylglycerol	0.57	1.45 (0.68 to 2.23)	0.014	1.05 (0.27 to 1.84)	0.157
Palmitate (16:0)	Long-chain saturated fatty acid	0.80	3.51 (1.62 to 5.41)	0.014	3.11 (1.26 to 4.97)	0.054
Cis-4-decenoate	Medium-chain fatty acid	...	2.06 (0.95 to 3.17)	0.014	2.03 (0.95 to 3.11)	0.021
1-myristoyl-2-arachidonoyl-GPC (14:0/20:4)†	PC	...	2.29 (1.05 to 3.53)	0.014	1.59 (0.33 to 2.85)	0.188
5-dodecenoylcarnitine (C12:1)	Fatty acid metabolism (acyl carnitine, monounsaturated)	0.50	1.43 (0.66 to 2.2)	0.014	1.53 (0.78 to 2.29)	0.009
1-dihomo-linoleoylglycerol (20:2)	Monoacylglycerol	0.64	1.39 (0.62 to 2.15)	0.018	1.06 (0.3 to 1.83)	0.141
Octanoylcarnitine (C8)	Fatty acid metabolism (acyl carnitine, medium chain)	0.51	1.74 (0.78 to 2.71)	0.018	1.83 (0.9 to 2.77)	0.014
1-linoleoylglycerol (18:2)	Monoacylglycerol	0.63	1.54 (0.68 to 2.39)	0.018	1.14 (0.28 to 2)	0.161
1-dihomo-linolenylglycerol (20:3)	Monoacylglycerol	0.66	1.49 (0.65 to 2.33)	0.020	1.02 (0.17 to 1.87)	0.225
Palmitoylcarnitine (C16)†	Fatty acid metabolism (acyl carnitine, long-chain saturated)	0.50	3.57 (1.55 to 5.59)	0.021	3.33 (1.36 to 5.3)	0.051
Tetrahydrocortisone glucuronide (5)	Corticosteroids	...	1.65 (0.7 to 2.6)	0.024	1.22 (0.27 to 2.17)	0.182
1-palmitoyl-2-arachidonoyl-GPI (16:0/20:4)†	PI	...	2.6 (1.11 to 4.1)	0.024	2.19 (0.72 to 3.67)	0.112
Sphingomyelin (d18:2/16:0, d18:1/16:1)†	Sphingomyelins	...	5.09 (2.15 to 8.03)	0.024	3.9 (0.97 to 6.82)	0.161
Hexanoylcarnitine (C6)	Fatty acid metabolism (acyl carnitine, medium chain)	0.55	1.79 (0.75 to 2.83)	0.025	1.83 (0.82 to 2.84)	0.027
Sphingomyelin (d18:2/14:0, d18:1/14:1)†	Sphingomyelins	...	3.31 (1.38 to 5.24)	0.025	2.36 (0.42 to 4.3)	0.217
1-arachidonoyl-GPI (20:4)	Lysophospholipid	0.55	3.53 (1.46 to 5.6)	0.026	2.99 (0.95 to 5.02)	0.118

(Continued)

Table 3. Continued

Metabolites	Pathway	Loading in lipid pattern*	Model 1		Model 2	
			Coefficient (95% CI)	Q value	Coefficient (95% CI)	Q value
Sphingomyelin (d18:1/14:0, d16:1/16:0)†	Sphingomyelins	...	3.95 (1.63 to 6.27)	0.026	2.65 (0.29 to 5.01)	0.279
Cholesterol†	Sterol	...	4.78 (1.98 to 7.59)	0.026	4.15 (1.4 to 6.9)	0.112
2-palmitoleoylglycerol (16:1)	Monoacylglycerol	0.46	1.14 (0.46 to 1.82)	0.031	0.81 (0.13 to 1.5)	0.237
Hydantoin-5-propionate	Histidine metabolism	...	1.45 (0.58 to 2.32)	0.032	1.32 (0.47 to 2.17)	0.094
1-palmitoyl-2-arachidonoyl-GPC (16:0/20:4n6)†	PC	...	3.94 (1.55 to 6.33)	0.035	2.94 (0.55 to 5.32)	0.206
p-cresol sulfate	Benzoate metabolism	...	-1.01 (-1.63 to -0.4)	0.036	-0.88 (-1.48 to -0.27)	0.118
Palmitoleate (16:1n7)	Long-chain monounsaturated fatty acid	0.70	1.8 (0.69 to 2.91)	0.040	1.71 (0.63 to 2.79)	0.077

Coefficient indicates DBP (mmHg) associated with a fold increase of the abundance of a given metabolite in linear regression (N=434). Model 1 was adjusted for age, sex, provinces, batch, urbanization index, per-capita household income, education, total energy intake, animal-source food, sodium, physical activity, smoking, alcohol, and estimated glomerular filtration rate. Model 2 was additionally adjusted for body mass index. DBP indicates diastolic blood pressure; GPC, glycerophosphocholine; PC, phosphatidylcholine; and PI, phosphatidylinositol.

*Pattern was derived from principal component analysis followed by a varix rotation. Loadings > 0.4 are listed.

†Metabolites also associated with systolic blood pressure.

hypertension in hypertensive rats fed a high-salt diet.⁵⁰ In line with our findings, Menni et al. showed that in 3980 TwinsUK females, a few plasma carnitines, long-chain fatty acids, and steroids were positively associated with BP, including hexadecanedioate, palmitate (16:0), octanoylcarnitine (C8), 10-heptadecenoate (17:1n7), and dihomolinoleate (20:2n6).¹⁵ In particular, hexadecanedioate, a dicarboxylic acid, consistently showed positive association with BP in 2 replication cohorts with both males and females.¹⁵ Subsequent analysis using rat model demonstrated that oral intake of hexadecanedioate increased BP, supporting a causal role of hexadecanedioate in BP regulation.¹⁵ In another study of 202 African and White men, serum long-chain and medium-chain acyl-carnitines (in Whites only) were positively associated with ambulatory BP.⁵¹ Similarly, we found

positive associations between medium- and long-chain acyl-carnitines, long-chain fatty acids, and a lipid pattern driven by long-chain fatty acids with BP. Elevated levels of circulating acyl-carnitines and long-chain fatty acids may contribute to hypertension development, as acyl-carnitines are byproducts of incomplete β -oxidation and can accumulate in blood or urine when fatty acids are in excess for oxidation, thus stimulating proinflammatory pathways involving nuclear factor kappa B.⁵² Likewise, omega-6 fatty acid like linoleate may impair cardiovascular health as it can be metabolized to dihomolinoleate and then to arachidonic acid, a precursor for proinflammatory eicosanoids like leukotriene B₄.⁵³

In addition, we found that several sphingomyelins and the sphingomyelin metabolic pathway were each positively associated with BP. Ceramide as a precursor for

Table 4. Metabolic Pathways Associated With SBP or DBP

Metabolic pathways	m*	SBP				DBP			
		k*	Enrichment score*	P value†	Q value†	k*	Enrichment score*	P value†	Q value†
Corticosteroids	6	0	3	12.47	0.001	0.005
Diacylglycerol	3	2	18.77	0.004	0.019	0
Fatty acid metabolism (acyl carnitine, long-chain saturated)	6	3	14.48	9×10^{-4}	0.009	3	12.47	0.001	0.005
Fatty acid metabolism (acyl carnitine, medium chain)	6	1	4.54	0.206	0.301	4	17.10	4×10^{-5}	3×10^{-4}
Monoacylglycerol	14	1	1.93	0.418	0.496	5	9.35	0.0002	0.001
PC	18	4	6.56	0.004	0.019	2	2.66	0.180	0.337
PI	5	2	11.24	0.013	0.049	2	9.72	0.017	0.048
Sphingomyelins	28	8	9.63	3×10^{-6}	6×10^{-5}	8	8.07	1×10^{-5}	2×10^{-4}

BP indicates blood pressure; DBP, diastolic BP; PC, phosphatidylcholine; PI, phosphatidylinositol; and SBP, systolic BP.

*Enrichment score was calculated using $(k/m)/[(n-k)/(N-m)]$, where k and n are numbers of BP-associated metabolites (model 1 false discovery rate adjusted $P < 0.05$) in a given pathway and all identified pathways (SBP: n=34; DBP: n=39), respectively; m and N are numbers of classified metabolites in a given pathway and all identified pathways (N=904), respectively.

†P value for each pathway was calculated using Fisher exact test and adjusted for false discovery rate (Q value) across pathways containing at least one BP-associated metabolite.

sphingolipids is harmful to cardiovascular health, including impaired vasodilation.⁵⁴ Excess sphingolipids occur when fatty acids exceed energy need or storage capacity of a cell.⁵⁵ Several lipidomic studies have identified sphingolipids as candidate blood markers for cardiovascular diseases in humans.^{56–58} For example, Poss et al⁵⁸ found that 30 serum sphingolipids were elevated in subjects with coronary artery disease (n=462) than controls (n=212) and a sphingolipid risk score was more effective than conventional biomarkers like triglycerides and LDL-C in distinguishing coronary artery disease patients.

The strengths of our study include paired microbiota and metabolite data in a well-characterized cohort with clinically measured BP. Moreover, the rich sociodemographic and behavioral data of the CHNS allowed us to account for a wide range of potential confounders. The low treatment rate for hypertension ensured sufficient sample size and large variation in BP, even after excluding people who took antihypertension medication to minimize medication effects. However, we cannot infer a causal relationship between gut microbiota, host metabolome, and BP due to the cross-sectional design, and our microbial 16S rRNA data did not provide functional information. Future studies are needed to confirm our findings, particularly, population-based studies with repeated measures paired with experimental studies to investigate the causal biological pathways modulating BP.

PERSPECTIVES

Our study provides substantial observational evidence for the associations between gut microbiota and plasma metabolites with BP in a population-based cohort of middle-aged Chinese adults. The overall microbial community varied by BP. Several individual metabolites (eg, lignoceroyl sphingomyelin, cerotylcarnitine, and dihomolinolenate) and an overall lipid metabolite pattern characterized by long-chain fatty acids were positively associated with BP, suggesting a role of circulating lipids in hypertension. Further analyses with longitudinal data and refined microbial composition data in larger samples are needed to fully elucidate the causal relationship between gut microbiota, host metabolites, and BP, thereby informing effective early interventions and treatments for hypertension.

ARTICLE INFORMATION

Received August 12, 2020; accepted November 10, 2020.

Affiliations

From the Department of Nutrition (Y.W., M.C.B.T., K.A.M., P.G.-L.), Department of Biostatistics (A.G.H.), and Department of Epidemiology (M.C.B.T., C.L.A.), Gillings School of Global Public Health & School of Medicine, Carolina Population Center (A.G.H., M.C.B.T., C.L.A., P.G.-L.), and Nutrition Research Institute (K.A.M.), University of North Carolina at Chapel Hill (UNC-Chapel Hill); National Institute for Nutrition and Health, Chinese Center for Disease Control and Prevention, Beijing (H.W., J.Z., C.S., Z.W., B.Z.); Department of Cancer Biostatistics, Levine Cancer

Institute, Atrium Health, Charlotte, NC (W.S.); and Department of Bioinformatics and Genomics, University of North Carolina at Charlotte (W.S., S.S., A.A.F.).

Acknowledgments

We thank Dr Misa Graff and Dr Kari North for assistance with methodology, and Dr Shufa Du, Guifeng Jin, and Dr Hsiao-Chuan Tien for database assistance.

Sources of Funding

This work was supported by the National Institutes of Health (NIH) and National Institute of Diabetes and Digestive and Kidney Diseases (R01-DK104371). We are grateful to the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) for R01 HD30880 and the NIH Fogarty grant D43 TW009077 for financial support for the China Health and Nutrition Survey (CHNS) data collection and analysis files from 1989 to 2015 and future surveys. We are also grateful for funding from the NICHD to Carolina Population Center (CPC) at the University of North Carolina at Chapel Hill (NIH grant P2C HD050924) and for pilot funds leading to the data herein from the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health, through Grant Award Number UL1TR002489. We thank the National Institute for Nutrition and Health (NINH) and China Center for Disease Control and Prevention (CCDC). Y. Wang is grateful to the Sanofi funding award 29230-50347-466001 for educational support. M.C.B. Tsilimigras is supported by Ruth L. Kirschstein National Research Service Awards (NRSA) Genetic Epidemiology of Heart, Lung, and Blood (HLB) Traits Training Grant (GenHLB, T32HL129982) funded by National Heart, Lung, and Blood Institute (NHLBI).

Disclosures

None.

REFERENCES

1. Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Chang AR, Cheng S, Das SR, et al; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2019 Update: a report from the American Heart Association. *Circulation*. 2019;139:e56–e528. doi: 10.1161/CIR.0000000000000659
2. Mills KT, Bundy JD, Kelly TN, Reed JE, Kearney PM, Reynolds K, Chen J, He J. Global burden of hypertension: analysis of population-based studies from 89 countries. *J Hypertens*. 2015;33:e2.
3. Fryar CD, Ostchega Y, Hales CM, Zhang G, Kruszon-Moran D. Hypertension prevalence and control among adults: United States, 2015–2016. *NCHS Data Brief*. 2017;(289):1–8.
4. Lu X, Wang L, Lin X, Huang J, Charles Gu C, He M, Shen H, He J, Zhu J, Li H, et al. Genome-wide association study in Chinese identifies novel loci for blood pressure and hypertension. *Hum Mol Genet*. 2015;24:865–874. doi: 10.1093/hmg/ddu478
5. He J, Gu D, Chen J, Jaquish CE, Rao DC, Hixson JE, Chen JC, Duan X, Huang JF, Chen CS, et al; GenSalt Collaborative Research Group. Gender difference in blood pressure responses to dietary sodium intervention in the GenSalt study. *J Hypertens*. 2009;27:48–54. doi: 10.1097/hjh.0b013e328316bb87
6. Rothschild D, Weissbrod O, Barkan E, Kurilshikov A, Korem T, Zeevi D, Costea PI, Godneva A, Kalka IN, Bar N, et al. Environment dominates over host genetics in shaping human gut microbiota. *Nature*. 2018;555:210–215. doi: 10.1038/nature25973
7. Long T, Hicks M, Yu HC, Biggs WH, Kirkness EF, Menni C, Zierer J, Small KS, Mangino M, Messier H, et al. Whole-genome sequencing identifies common-to-rare variants associated with human blood metabolites. *Nat Genet*. 2017;49:568–578. doi: 10.1038/ng.3809
8. Yang T, Richards EM, Pepine CJ, Raizada MK. The gut microbiota and the brain-gut-kidney axis in hypertension and chronic kidney disease. *Nat Rev Nephrol*. 2018;14:442–456.
9. Pluznick J. A novel SCFA receptor, the microbiota, and blood pressure regulation. *Gut Microbes*. 2014;5:202–207.
10. Mell B, Jala VR, Mathew AV, Byun J, Waghulde H, Zhang Y, Haribabu B, Vijay-Kumar M, Pennathur S, Joe B. Evidence for a link between gut microbiota and hypertension in the Dahl rat. *Physiol Genomics*. 2015;47:187–197. doi: 10.1152/physiolgenomics.00136.2014
11. Yang T, Santisteban MM, Rodriguez V, Li E, Ahmari N, Carvajal JM, Zadeh M, Gong M, Qi Y, Zubevcic J, et al. Gut dysbiosis is linked to hypertension. *Hypertension*. 2015;65:1331–1340. doi: 10.1161/HYPERTENSIONAHA.115.05315

12. Morris DJ, Latif SA, Hardy MP, Brem AS. Endogenous inhibitors (GALFs) of 11beta-hydroxysteroid dehydrogenase isoforms 1 and 2: derivatives of adrenally produced corticosterone and cortisol. *J Steroid Biochem Mol Biol*. 2007;104:161–168. doi: 10.1016/j.jsbmb.2007.03.020
13. Li J, Zhao F, Wang Y, Chen J, Tao J, Tian G, Wu S, Liu W, Cui Q, Geng B, et al. Gut microbiota dysbiosis contributes to the development of hypertension. *Microbiome*. 2017;5:14. doi: 10.1186/s40168-016-0222-x
14. Silveira-Nunes G, Durso DF, Jr LRAO, Cunha EHM, Maioli TU, Vieira AT, Speziali E, Corrêa-Oliveira R, Martins-Filho OA, Teixeira-Carvalho A, et al. Hypertension is associated with intestinal microbiota dysbiosis and inflammation in a Brazilian population. *Front Pharmacol*. 2020;11:258. doi: 10.3389/fphar.2020.00258
15. Menni C, Graham D, Kastenmüller G, Alharbi NH, Alsanosi SM, McBride M, Mangino M, Titcombe P, Shin SY, Psatha M, et al. Metabolomic identification of a novel pathway of blood pressure regulation involving hexadecanedioate. *Hypertension*. 2015;66:422–429. doi: 10.1161/HYPERTENSIONAHA.115.05544
16. Zheng Y, Yu B, Alexander D, Mosley TH, Heiss G, Nettleton JA, Boerwinkle E. Metabolomics and incident hypertension among blacks: the atherosclerosis risk in communities study. *Hypertension*. 2013;62:398–403. doi: 10.1161/HYPERTENSIONAHA.113.01166
17. Adnan S, Nelson JW, Ajami NJ, Venna VR, Petrosino JF, Bryan RM Jr, Durgan DJ. Alterations in the gut microbiota can elicit hypertension in rats. *Physiol Genomics*. 2017;49:96–104. doi: 10.1152/physiolgenomics.00081.2016
18. Sun S, Lulla A, Sioda M, Winglee K, Wu MC, Jacobs DR Jr, Shikany JM, Lloyd-Jones DM, Launer LJ, Fodor AA, et al. Gut microbiota composition and blood pressure. *Hypertension*. 2019;73:998–1006. doi: 10.1161/HYPERTENSIONAHA.118.12109
19. Wang Z, Chen Z, Zhang L, Wang X, Hao G, Zhang Z, Shao L, Tian Y, Dong Y, Zheng C, et al; China Hypertension Survey Investigators. Status of hypertension in China: results from the China Hypertension Survey, 2012–2015. *Circulation*. 2018;137:2344–2356. doi: 10.1161/CIRCULATIONAHA.117.032380
20. Xi B, Liang Y, Reilly KH, Wang Q, Hu Y, Tang W. Trends in prevalence, awareness, treatment, and control of hypertension among Chinese adults 1991–2009. *Int J Cardiol*. 2012;158:326–329. doi: 10.1016/j.ijcard.2012.04.140
21. Popkin BM, Du S, Zhai F, Zhang B. Cohort profile: The China Health and Nutrition Survey—monitoring and understanding socio-economic and health change in China, 1989–2011. *Int J Epidemiol*. 2010;39:1435–1440. doi: 10.1093/ije/dyp322
22. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, et al; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. *Hypertension*. 2003;42:1206–1252. doi: 10.1161/01.HYP.0000107251.49515.c2
23. Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, Ramirez A, Schlaich M, Stergiou GS, Tomaszewski M, et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. *Hypertension*. 2020;75:1334–1357. doi: 10.1161/HYPERTENSIONAHA.120.15026
24. Caporaso JG, Kuczynski J, Stombaugh J, Bittinger K, Bushman FD, Costello EK, Fierer N, Peña AG, Goodrich JK, Gordon JL, et al. QIIME allows analysis of high-throughput community sequencing data. *Nat Methods*. 2010;7:335–336. doi: 10.1038/nmeth.f.303
25. Haas BJ, Gevers D, Earl AM, Feldgarden M, Ward DV, Giannoukos G, Ciulla D, Tabbaa D, Highlander SK, Sodergren E, et al; Human Microbiome Consortium. Chimeric 16S rRNA sequence formation and detection in Sanger and 454-pyrosequenced PCR amplicons. *Genome Res*. 2011;21:494–504. doi: 10.1101/gr.112730.110
26. Sumner LW, Amberg A, Barrett D, Beale MH, Beger R, Daykin CA, Fan TW, Fiehn O, Goodacre R, Griffin JL, et al. Proposed minimum reporting standards for chemical analysis Chemical Analysis Working Group (CAWG) Metabolomics Standards Initiative (MSI). *Metabolomics*. 2007;3:211–221. doi: 10.1007/s11306-007-0082-2
27. Jones-Smith JC, Popkin BM. Understanding community context and adult health changes in China: development of an urbanicity scale. *Soc Sci Med*. 2010;71:1436–1446. doi: 10.1016/j.socscimed.2010.07.027
28. Yao M, Lichtenstein AH, Roberts SB, Ma G, Gao S, Tucker KL, McCrory MA. Relative influence of diet and physical activity on cardiovascular risk factors in urban Chinese adults. *Int J Obes Relat Metab Disord*. 2003;27:920–932. doi: 10.1038/sj.ijo.0802308
29. Batis C, Gordon-Larsen P, Cole SR, Du S, Zhang B, Popkin B. Sodium intake from various time frames and incident hypertension among Chinese adults. *Epidemiology*. 2013;24:410–418. doi: 10.1097/EDE.0b013e318289e047
30. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, et al; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. *Ann Intern Med*. 2009;150:604–612. doi: 10.7326/0003-4819-150-9-200905050-00006
31. Oksanen J, Kindt R, Legendre P, O'Hara B, Stevens M, Oksanen M, Suggests M. The vegan package: community ecology package. *R Pack Vers*. 2007;1:15–11.
32. Peet RK. The measurement of species diversity. *Annu Rev Ecol Syst*. 1974;5:285–307.
33. Faith DP, Minchin PR, Belbin L. Compositional dissimilarity as a robust measure of ecological distance. *Vegetation*. 1987;69:57–68.
34. Anderson MJ. Permutational multivariate analysis of variance (PERMANOVA). *Wiley StatsRef: Statistics Reference Online*. 2014;1–15. doi: 10.1002/9781118445112.stat07841
35. Winglee K, Howard AG, Sha W, Gharraibeh RZ, Liu J, Jin D, Fodor AA, Gordon-Larsen P. Recent urbanization in China is correlated with a Westernized microbiome encoding increased virulence and antibiotic resistance genes. *Microbiome*. 2017;5:121. doi: 10.1186/s40168-017-0338-7
36. Popkin BM, Du S. Dynamics of the nutrition transition toward the animal foods sector in China and its implications: a worried perspective. *J Nutr*. 2003;133(11 Suppl 2):3898S–3906S. doi: 10.1093/jn/133.11.3898S
37. Du S, Neiman A, Batis C, Wang H, Zhang B, Zhang J, Popkin BM. Understanding the patterns and trends of sodium intake, potassium intake, and sodium to potassium ratio and their effect on hypertension in China. *Am J Clin Nutr*. 2014;99:334–343. doi: 10.3945/ajcn.113.059121
38. Sekula P, Goek ON, Quaye L, Barrios C, Levey AS, Römisch-Margl W, Menni C, Yet I, Gieger C, Inker LA, et al. A metabolome-wide association study of kidney function and disease in the general population. *J Am Soc Nephrol*. 2016;27:1175–1188. doi: 10.1681/ASN.2014111099
39. Antonelli J, Claggett BL, Henglin M, Kim A, Ovsak G, Kim N, Deng K, Rao K, Tyagi O, Watrous JD. Statistical workflow for feature selection in human metabolomics data. *Metabolites*. 2019;9:143.
40. Conway JM, Huffcutt AI. A review and evaluation of exploratory factor analysis practices in organizational research. *Org Res Methods*. 2003;6:147–168.
41. McDonald JH. *Handbook of Biological Statistics*. Baltimore, MD: Sparky House Publishing; 2009.
42. Pedregosa F, Varoquaux G, Gramfort A, Michel V, Thirion B, Grisel O, Blondel M, Prettenhofer P, Weiss R, Dubourg V. Scikit-learn: machine learning in Python. *J Mach Learn Res*. 2011;12:2825–2830.
43. Dietterich TG. Approximate statistical tests for comparing supervised classification learning algorithms. *Neural Comput*. 1998;10:1895–1923. doi: 10.1162/089976698300017197
44. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. *J R Stat Soc Ser B (Methodological)*. 1995;57:289–300.
45. Holmes E, Loo RL, Stalmer J, Bictash M, Yap IK, Chan O, Ebbels T, De Iorio M, Brown IJ, Veselkov KA, et al. Human metabolic phenotype diversity and its association with diet and blood pressure. *Nature*. 2008;453:396–400. doi: 10.1038/nature06882
46. Chen YY, Chen DQ, Chen L, Liu JR, Vaziri ND, Guo Y, Zhao YY. Microbiome-metabolome reveals the contribution of gut-kidney axis on kidney disease. *J Transl Med*. 2019;17:5. doi: 10.1186/s12967-018-1756-4
47. Kindt R, Liebisch G, Clavel T, Haller D, Hörmannspurger G, Yoon H, Kolmeder D, Sigrüener A, Krautbauer S, Seeliger C, et al. The gut microbiota promotes hepatic fatty acid desaturation and elongation in mice. *Nat Commun*. 2018;9:3760. doi: 10.1038/s41467-018-05767-4
48. Cheema MU, Pluznick JL. Gut microbiota plays a central role to modulate the plasma and fecal metabolomes in response to Angiotensin II. *Hypertension*. 2019;74:184–193. doi: 10.1161/HYPERTENSIONAHA.119.13155
49. Pallister T, Jackson MA, Martin TC, Zierer J, Jennings A, Mohny RP, MacGregor A, Steves CJ, Cassidy A, Spector TD, et al. Hippurate as a metabolomic marker of gut microbiome diversity: Modulation by diet and relationship to metabolic syndrome. *Sci Rep*. 2017;7:13670. doi: 10.1038/s41598-017-13722-4
50. Chakraborty S, Galla S, Cheng X, Yeo JY, Mell B, Singh V, Yeoh B, Saha P, Mathew AV, Vijay-Kumar M, et al. Salt-responsive metabolite, β -hydroxybutyrate, attenuates hypertension. *Cell Rep*. 2018;25:677–689.e4. doi: 10.1016/j.celrep.2018.09.058

51. Mels CM, Schutte AE, Erasmus E, Huisman HW, Schutte R, Fourie CM, Kruger R, Van Rooyen JM, Smith W, Malan NT, et al. L-carnitine and long-chain acylcarnitines are positively correlated with ambulatory blood pressure in humans: the SABPA study. *Lipids*. 2013;48:63–73. doi: 10.1007/s11745-012-3732-8
52. Adams SH, Hoppel CL, Lok KH, Zhao L, Wong SW, Minkler PE, Hwang DH, Newman JW, Garvey WT. Plasma acylcarnitine profiles suggest incomplete long-chain fatty acid beta-oxidation and altered tricarboxylic acid cycle activity in type 2 diabetic African-American women. *J Nutr*. 2009;139:1073–1081. doi: 10.3945/jn.108.103754
53. Harris WS, Shearer GC. Omega-6 fatty acids and cardiovascular disease: friend, not foe? *Circulation*. 2014;130:1562–1564. doi: 10.1161/CIRCULATIONAHA.114.012534
54. Chaurasia B, Summers SA. Ceramides—lipotoxic inducers of metabolic disorders. *Trends Endocrinol Metab*. 2015;26:538–550. doi: 10.1016/j.tem.2015.07.006
55. Summers SA, Chaurasia B, Holland WL. Metabolic messengers: ceramides. *Nat Metab*. 2019;1:1051–1058. doi: 10.1038/s42255-019-0134-8
56. Havulinna AS, Sysi-Aho M, Hilvo M, Kauhanen D, Hurme R, Ekroos K, Salomaa V, Laaksonen R. Circulating ceramides predict cardiovascular outcomes in the population-based FINRISK 2002 cohort. *Arterioscler Thromb Vasc Biol*. 2016;36:2424–2430. doi: 10.1161/ATVBAHA.116.307497
57. Laaksonen R, Ekroos K, Sysi-Aho M, Hilvo M, Vihervaara T, Kauhanen D, Suoniemi M, Hurme R, März W, Scharnagl H, et al. Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol. *Eur Heart J*. 2016;37:1967–1976. doi: 10.1093/eurheartj/ehw148
58. Poss AM, Maschek JA, Cox JE, Hauner BJ, Hopkins PN, Hunt SC, Holland WL, Summers SA, Playdon MC. Machine learning reveals serum sphingolipids as cholesterol-independent biomarkers of coronary artery disease. *J Clin Invest*. 2020;130:1363–1376. doi: 10.1172/JCI131838